相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。The Mechanism of Double-Strand DNA Break Repair by the Nonhomologous DNA End-Joining Pathway
Michael R. Lieber
ANNUAL REVIEW OF BIOCHEMISTRY, VOL 79 (2010)
Defective Mismatch Repair, Microsatellite Mutation Bias, and Variability in Clinical Cancer Phenotypes
Sandeep N. Shah et al.
CANCER RESEARCH (2010)
Poly(ADP-Ribose) Polymerase Is Hyperactivated in Homologous Recombination-Defective Cells
Ponnari Gottipati et al.
CANCER RESEARCH (2010)
PTEN Loss Compromises Homologous Recombination Repair in Astrocytes: Implications for Glioblastoma Therapy with Temozolomide or Poly(ADP-Ribose) Polymerase Inhibitors
Brian McEllin et al.
CANCER RESEARCH (2010)
BRCA1 and BRCA2: breast/ovarian cancer susceptibility gene products and participants in DNA double-strand break repair
Peter J. O'Donovan et al.
CARCINOGENESIS (2010)
Homologous recombination in cancer development, treatment and development of drug resistance
Thomas Helleday
CARCINOGENESIS (2010)
53BP1 Inhibits Homologous Recombination in Brca1-Deficient Cells by Blocking Resection of DNA Breaks
Samuel F. Bunting et al.
CELL (2010)
Monitoring Drug-Induced γH2AX as a Pharmacodynamic Biomarker in Individual Circulating Tumor Cells
Lihua H. Wang et al.
CLINICAL CANCER RESEARCH (2010)
Development of a Functional Assay for Homologous Recombination Status in Primary Cultures of Epithelial Ovarian Tumor and Correlation with Sensitivity to Poly(ADP-Ribose) Polymerase Inhibitors
Asima Mukhopadhyay et al.
CLINICAL CANCER RESEARCH (2010)
PARP inhibition: targeting the Achilles' heel of DNA repair to treat germline and sporadic ovarian cancers
Craig P. Carden et al.
CURRENT OPINION IN ONCOLOGY (2010)
Can molecular biomarker-based patient selection in Phase I trials accelerate anticancer drug development?
Craig P. Carden et al.
DRUG DISCOVERY TODAY (2010)
Poly(ADP-ribose) polymerase inhibitors in cancer treatment: A clinical perspective
Shahneen K. Sandhu et al.
EUROPEAN JOURNAL OF CANCER (2010)
Promising novel therapies for the treatment of endometrial cancer
Paola A. Gehrig et al.
GYNECOLOGIC ONCOLOGY (2010)
Gene Expression Profile of BRCAness That Correlates With Responsiveness to Chemotherapy and With Outcome in Patients With Epithelial Ovarian Cancer
Panagiotis A. Konstantinopoulos et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Somatic Mutations in BRCA1 and BRCA2 Could Expand the Number of Patients That Benefit From Poly (ADP Ribose) Polymerase Inhibitors in Ovarian Cancer
Bryan T. J. Hennessy et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Poly(ADP)-Ribose Polymerase Inhibition: Frequent Durable Responses in BRCA Carrier Ovarian Cancer Correlating With Platinum-Free Interval
Peter C. Fong et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Evolution of Poly(ADP-ribose) Polymerase-1 (PARP-1) Inhibitors. From Concept to Clinic
Dana V. Ferraris
JOURNAL OF MEDICINAL CHEMISTRY (2010)
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial
Andrew Tutt et al.
LANCET (2010)
PARP inhibition in BRCA-mutated breast and ovarian cancers
Stephen L. Chan et al.
LANCET (2010)
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial
M. William Audeh et al.
LANCET (2010)
ATM Deficiency Sensitizes Mantle Cell Lymphoma Cells to Poly(ADP-Ribose) Polymerase-1 Inhibitors
Chris T. Williamson et al.
MOLECULAR CANCER THERAPEUTICS (2010)
MECHANISMS OF DISEASE Susceptibility Pathways in Fanconi's Anemia and Breast Cancer
Alan D. D'Andrea
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Loss of poly(ADP-ribose) polymerase-2 leads to rapid development of spontaneous T-cell lymphomas in p53-deficient mice
L. Nicolas et al.
ONCOGENE (2010)
Envisioning the future of early anticancer drug development
Timothy A. Yap et al.
NATURE REVIEWS CANCER (2010)
Prediction of breast cancer sensitivity to neoadjuvant chemotherapy based on status of DNA damage repair proteins
Hideki Asakawa et al.
BREAST CANCER RESEARCH (2010)
BRCA1 promoter methylation is associated with increased mortality among women with breast cancer
Xinran Xu et al.
BREAST CANCER RESEARCH AND TREATMENT (2009)
Prediction of BRCA1-association in hereditary non-BRCA1/2 breast carcinomas with array-CGH
Simon A. Joosse et al.
BREAST CANCER RESEARCH AND TREATMENT (2009)
Germ-Line Mutations in Mismatch Repair Genes Associated with Prostate Cancer
Eli Marie Grindedal et al.
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION (2009)
A Phase IB Trial of Intravenous INO-1001 Plus Oral Temozolomide in Subjects with Unresectable Stage-III or IV Melanoma
Agop Y. Bedikian et al.
CANCER INVESTIGATION (2009)
Functional Restoration of BRCA2 Protein by Secondary BRCA2 Mutations in BRCA2-Mutated Ovarian Carcinoma
Wataru Sakai et al.
CANCER RESEARCH (2009)
Base excision repair of oxidative DNA damage and association with cancer and aging
Scott Maynard et al.
CARCINOGENESIS (2009)
Cell cycle checkpoint defects contribute to genomic instability in PTEN deficient cells independent of DNA DSB repair
Arun Gupta et al.
CELL CYCLE (2009)
γH2AX Expression in Tumors Exposed to Cisplatin and Fractionated Irradiation
C. Adriana Banuelos et al.
CLINICAL CANCER RESEARCH (2009)
Coordination of DNA Mismatch Repair and Base Excision Repair Processing of Chemotherapy and Radiation Damage for Targeting Resistant Cancers
Timothy J. Kinsella
CLINICAL CANCER RESEARCH (2009)
PARP is activated at stalled forks to mediate Mre11-dependent replication restart and recombination
Helen E. Bryant et al.
EMBO JOURNAL (2009)
Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors
Ana M. Mendes-Pereira et al.
EMBO MOLECULAR MEDICINE (2009)
Development of PARP inhibitors in oncology
Jordi Rodon et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2009)
Treatment outcomes and clinicopathologic characteristics of triple-negative breast cancer patients who received platinum-containing chemotherapy
Ji Eun Uhm et al.
INTERNATIONAL JOURNAL OF CANCER (2009)
Phase 0 Clinical Trial of the Poly (ADP-Ribose) Polymerase Inhibitor ABT-888 in Patients With Advanced Malignancies
Shivaani Kummar et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Utility of DNA Repair Protein Foci for the Detection of Putative BRCA1 Pathway Defects in Breast Cancer Biopsies
Henning Willers et al.
MOLECULAR CANCER RESEARCH (2009)
Targeting homologous recombination using imatinib results in enhanced tumor cell chemosensitivity and radiosensitivity
Ananya Choudhury et al.
MOLECULAR CANCER THERAPEUTICS (2009)
Disorders of nucleotide excision repair: the genetic and molecular basis of heterogeneity
James E. Cleaver et al.
NATURE REVIEWS GENETICS (2009)
Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers.
Peter C. Fong et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Gefitinib or Carboplatin-Paclitaxel in Pulmonary Adenocarcinoma.
Tony S. Mok et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
ETS family transcription factors collaborate with alternative signaling pathways to induce carcinoma from adult murine prostate cells
Yang Zong et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
Platinum-based chemotherapy in triple-negative breast cancer
B. Sirohi et al.
ANNALS OF ONCOLOGY (2008)
Ovarian carcinomas with genetic and epigenetic BRCA1 loss have distinct molecular abnormalities
Joshua Z. Press et al.
BMC CANCER (2008)
Secondary BRCA1 mutations in BRCA1-mutated ovarian carcinomas with platinum resistance
Elizabeth M. Swisher et al.
CANCER RESEARCH (2008)
Phase I Study of the Poly (ADP-Ribose) Polymerase Inhibitor, AG014699, in Combination with Temozolomide in Patients with Advanced Solid Tumors
Ruth Plummer et al.
CLINICAL CANCER RESEARCH (2008)
Targeting the PI3K-AKT-mTOR pathway: progress, pitfalls, and promises
Timothy A. Yap et al.
CURRENT OPINION IN PHARMACOLOGY (2008)
BRCAness Syndrome in Ovarian Cancer: A Case-Control Study Describing the Clinical Features and Outcome of Patients With Epithelial Ovarian Cancer Associated With BRCA1 and BRCA2 Mutations
David S. P. Tan et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
A synthetic lethal therapeutic approach: Poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair
Alan Ashworth
JOURNAL OF CLINICAL ONCOLOGY (2008)
Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers
Wataru Sakai et al.
NATURE (2008)
Resistance to therapy caused by intragenic deletion in BRCA2
Stacey L. Edwards et al.
NATURE (2008)
PTEN: a new guardian of the genome
Y. Yin et al.
ONCOGENE (2008)
High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs
Sven Rottenberg et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Triple negative tumours: a critical review
J. S. Reis-Filho et al.
HISTOPATHOLOGY (2008)
DNA repair pathways as targets for cancer therapy
Thomas Helleday et al.
NATURE REVIEWS CANCER (2008)
HDAC inhibitor PCI-24781 decreases RAD51 expression and inhibits homologous recombination
Shanthi Adimoolam et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
Targeting poly(ADP-ribose) polymerase: A two-armed strategy for cancer therapy
Elizabeth Ruth Plummer et al.
CLINICAL CANCER RESEARCH (2007)
Inhibitors of the proteasome suppress homologous DNA recombination in mammalian cells
Yasuhiro Murakawa et al.
CANCER RESEARCH (2007)
Frequent alteration of DNA damage signalling and repair pathways in human colorectal cancers with microsatellite instability
C. Miquel et al.
ONCOGENE (2007)
Proteasome function is required for DNA damage response and Fanconi anemia pathway activation
Celine Jacquemont et al.
CANCER RESEARCH (2007)
Utilizing RNA interference to enhance cancer drug discovery
Elizabeth Iorns et al.
NATURE REVIEWS DRUG DISCOVERY (2007)
Poly(ADP-ribose) polymerase-1 plays a role in suppressing mammary tumourigenesis in mice
W. M. Tong et al.
ONCOGENE (2007)
Essential role for nuclear PTEN in maintaining chromosomal integrity
Wen Hong Shen et al.
CELL (2007)
Population BRCA1 and BRCA2 mutation frequencies and cancer penetrances: A kin-cohort study in Ontario, Canada
Harvey A. Risch et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2006)
The roles of BRCA1 and BRCA2 and associated proteins in the maintenance of genomic stability
K. Gudmundsdottir et al.
ONCOGENE (2006)
Basal-like breast cancer and the BRCA1 phenotype
N. C. Turner et al.
ONCOGENE (2006)
Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition
Nuala McCabe et al.
CANCER RESEARCH (2006)
Cyclin-dependent kinase 2 functions in normal DNA repair and is a therapeutic target in BRCA1-deficient cancers
Andrew J. Deans et al.
CANCER RESEARCH (2006)
DNA repair pathways in clinical practice: Lessons from pediatric cancer susceptibility syndromes
Richard D. Kennedy et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
ATM mutations that cause ataxia-telangiectasia are breast cancer susceptibility alleles
Anthony Renwick et al.
NATURE GENETICS (2006)
Association of circulating tumor cells with serum tumor-related methylated DNA in peripheral blood of melanoma patients
Kazuo Koyanagi et al.
CANCER RESEARCH (2006)
The multifaceted mismatch-repair system
J Jiricny
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2006)
Global synthetic-lethality analysis and yeast functional profiling
SL Ooi et al.
TRENDS IN GENETICS (2006)
BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases
T Pal et al.
CANCER (2005)
Efficient deletion of normal Brca2-deficient intestinal epithelium by poly(ADP-ribose) polymerase inhibition models potential prophylactic therapy
T Hay et al.
CANCER RESEARCH (2005)
PTEN loss inhibits CHK1 to cause double stranded-DNA breaks in cells
J Puc et al.
CELL CYCLE (2005)
Cancer in xeroderma pigmentosum and related disorders of DNA repair
JE Cleaver
NATURE REVIEWS CANCER (2005)
Cancer risks and mortality in heterozygous ATM mutation carriers
D Thompson et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2005)
Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase
HE Bryant et al.
NATURE (2005)
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
H Farmer et al.
NATURE (2005)
The concept of synthetic lethality in the context of anticancer therapy
WG Kaelin
NATURE REVIEWS CANCER (2005)
Inactivation of the Fanconi anemia/BRCA pathway in lung and oral cancers: implications for treatment and survival
CJ Marsit et al.
ONCOGENE (2004)
PTEN mutations are common in sporadic microsatellite stable colorectal cancer
NT Nassif et al.
ONCOGENE (2004)
Hallmarks of 'BRCAness' in sporadic cancers
N Turner et al.
NATURE REVIEWS CANCER (2004)
Promoter hypermethylation of FANCF:: Disruption of Fanconi Anemia-BRCA pathway in cervical cancer
G Narayan et al.
CANCER RESEARCH (2004)
EMSY links the BRCA2 pathway to sporadic breast and ovarian cancer
L Hughes-Davies et al.
CELL (2003)
Repeated observation of breast tumor subtypes in independent gene expression data sets
T Sorlie et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
Breast and ovarian cancer
R Wooster et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Disruption of the Fanconi anemia-BRCA pathway in cisplatin-sensitive ovarian tumors
T Taniguchi et al.
NATURE MEDICINE (2003)
Improved survival in women with BRCA-associated ovarian carcinoma
I Cass et al.
CANCER (2003)
The future of cytotoxic therapy: selective cytotoxicity based on biology is the key
JS de Bono et al.
BREAST CANCER RESEARCH (2003)
Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors
GD Demetri et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)
Gene expression profiles, of BRCA1-linked, BRCA2-linked, and sporadic ovarian cancers
AA Jazaeri et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2002)
Cancer susceptibility and the functions of BRCA1 and BRCA2
AR Venkitaraman
CELL (2002)
Genome maintenance mechanisms for preventing cancer
JHJ Hoeijmakers
NATURE (2001)
Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer
HA Risch et al.
AMERICAN JOURNAL OF HUMAN GENETICS (2001)
Gene-expression profiles in hereditary breast cancer.
I Hedenfalk et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors
M Esteller et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2000)
Mantle cell lymphoma is characterized by inactivation of the ATM gene
C Schaffner et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2000)
分享论文
